Sign in

SLN on Nasdaq

Silence Therapeutics

British pharmaceutical company

Silence Therapeutics (Nasdaq: SLN) is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1994Founded1

Compare with Trevena Inc, Yarrow Bioscience, Inc. or Quantum Cyber N.V., or pick any stock.

  • TickerSLN on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersLondon1
  • Websitewww.silence-therapeutics.com
  • Incorporated inUnited Kingdom5
  • Business address12 Hammersmith Grove, Office 205, London, W6 7Ap5
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formPublic Limited Company4
  • LEI213800SSURRJBX85SQ914
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address27 EASTCASTLE STREET, W1W 8DH London, United Kingdom4
  • Registered withCompanies House, 029920584

See how the biggest companies compare on our leaderboards

Silence Therapeutics (Nasdaq: SLN) is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

61.5%Gross margin6
-16292.8%Operating margin6
-15851.9%Net margin6
-98.7%Revenue growth, 20256
-142.2%Return on equity6
-$62.3MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue0¢$215.0K
  • Research and development100¢$67.8M
  • Income tax0¢$11.0K

Out of $559.0K in revenue.6 The company lost money this year.

Financial statements

Revenue786$559.0K in 2025−89% since 2020
0$20.0M$40.0M$60.0M2020: $5.3M$5.3M20202022: $21.7M$21.7M2022+309%2023: $31.6M$31.6M2023+46%2024: $43.3M$43.3M2024+37%2025: $559.0K$559.0K2025−99%
Gross profit971086$344.0K in 2025+41% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $244.0K$244.0K20192020: $1.7M$1.7M2020+604%2021: $5.0M$5.0M2021+189%2022: $8.2M$8.2M2022+65%2023: $18.8M$18.8M2023+129%2024: $31.4M$31.4M2024+67%2025: $344.0K$344.0K2025−99%
Operating income971086-$91.1M in 2025+301% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$22.7M-$22.7M20192020: -$35.8M-$35.8M2020+58%2021: -$45.8M-$45.8M2021+28%2022: -$61.0M-$61.0M2022+33%2023: -$64.4M-$64.4M2023+5%2024: -$63.3M-$63.3M2024−2%2025: -$91.1M-$91.1M2025+44%
Net income971086-$88.6M in 2025+353% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$19.6M-$19.6M20192020: -$32.5M-$32.5M2020+66%2021: -$39.4M-$39.4M2021+21%2022: -$50.3M-$50.3M2022+28%2023: -$54.2M-$54.2M2023+8%2024: -$45.3M-$45.3M2024−16%2025: -$88.6M-$88.6M2025+96%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Revenue$559.0K$43.3M$31.6M
Cost of sales-$215.0K-$11.8M
Gross profit$344.0K$31.4M
Research and development costs-$67.8M-$67.9M
General and administrative expenses-$22.3M-$26.9M
Restructuring charges-$1.3M$0
Operating loss-$91.1M-$63.3M
Foreign currency (loss)/gain, net-$8.5M$646.0K
Other income, net$3.5M$4.5M
Benefit from R&D credit$7.5M$13.7M
Loss before income tax expense-$88.6M-$44.5M
Income tax expense-$11.0K-$845.0K
Net Loss-$88.6M-$45.3M
Loss per share basic-$0.63-$0.33
Loss per share diluted-$0.63-$0.33
Weighted-average shares outstanding basic141.7M shares138.8M shares
Weighted-average shares outstanding diluted141.7M shares138.8M shares

Compare Silence Therapeutics with another company

Corporate structure

Silence Therapeutics sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Silence Therapeutics

  • Silence Therapeutics London, United Kingdom
    • Silence Therapeutics (Germany) Subsidiary · Germany

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Silence Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$5.5M6 Dec 31, 2025$6.3M6 Dec 31, 2024−12.6%
Accumulated depreciation$4.0M6 Dec 31, 2025$4.5M6 Dec 31, 2024−12.5%
Property and equipment, net$1.6M6 Dec 31, 2025$1.8M6 Dec 31, 2024−13.0%
Operating-lease assets (leased space)$167.0K6 Dec 31, 2025$157.0K6 Dec 31, 2024+6.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.3M6 Dec 31, 2025$121.3M6 Dec 31, 2024−90.7%
Marketable securities, current$73.8M6 Dec 31, 2025$26.0M6 Dec 31, 2024+183.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$10.6M6 Dec 31, 2025$9.4M6 Dec 31, 2024+13.1%
Intangible assets, net (excluding goodwill)$288.0K6 Dec 31, 2025$312.0K6 Dec 31, 2024−7.7%

Properties, in its own words

We lease office space in London, England for our corporate headquarters and general and administrative functions, which consists of approximately 4,000 square feet, under a lease with a term through September 2027. We also lease regional offices and laboratory space in Berlin, Germany (two leases: rolling contract basis with either party being able to end the lease upon 11.5 months’ prior notice) and Hoboken, New Jersey, USA (six leases: current lease end dates of April 2026, August 2026, October 2026, with either party being able to end the lease upon three months' prior notice).

We believe that our current facilities are adequate to meet our needs for the near future and that suitable additional or alternative space will be available on commercially reasonable terms to accommodate our foreseeable future operations.

Item 2 of the 10-K filed Mar 5, 2026.13

Leadership

Who has led Silence Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Craig A. Tooman2025

President

  1. Craig A. Tooman2025

Chief financial officer

  1. Rhonda Lynette Hellums2025–now
1995200020052010201520202025
Board members and other officers (9)

Subsidiaries and ownership

Subsidiaries

  • Silence Therapeutics (Germany)

From Wikidata.1

Timeline

  1. Aug 12, 20268-K Entered a material agreement; Other events24
  2. Aug 10, 20268-K Results of operations25
  3. Aug 10, 20268-K Regulation FD disclosure; Other events26
  4. Jul 16, 20268-K Executive or director change27
  5. Jun 23, 20268-K Regulation FD disclosure28
  6. Jun 16, 20268-K Shareholder vote29
  7. Jun 11, 20268-K Other events30
  8. May 18, 20268-K Entered a material agreement; Ended a material agreement; Other events31
  9. May 7, 20268-K Results of operations32
  10. Mar 5, 20268-K Results of operations; Regulation FD disclosure33
  11. Dec 22, 20258-K Executive or director change34
  12. Dec 22, 20258-K Executive or director change35
  13. Jan 2, 2025New chief executive Craig A. Tooman becomes CEO14
  14. 1994Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.45) a share, on Nov 6, 2025.36

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results25
  2. May 7, 2026Reported quarterly or annual results32
  3. Mar 5, 2026Reported quarterly or annual results33
  4. Nov 6, 2025Reported quarterly or annual results37
  5. Aug 7, 2025Reported quarterly or annual results38
  6. May 8, 2025Reported quarterly or annual results39
  7. Feb 27, 2025Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

208 filings to the SEC since October 2021: 6 annual reports, 5 quarterly reports, 22 major events, 52 insider forms, 38 large holders, 85 other. The latest 20:

  1. Oct 13, 2026SCHEDULE 13G/A EDGAR
  2. Oct 13, 2026SCHEDULE 13G EDGAR
  3. Aug 13, 2026SCHEDULE 13G/A EDGAR
  4. Aug 13, 2026SCHEDULE 13D/A EDGAR
  5. Aug 13, 20264 OWNERSHIP DOCUMENT EDGAR
  6. Aug 12, 20268-K EDGAR
  7. Aug 12, 2026424B5 EDGAR
  8. Aug 11, 2026S-3MEF EDGAR
  9. Aug 10, 2026424B5 EDGAR
  10. Aug 10, 20268-K EDGAR
  11. Aug 10, 202610-Q EDGAR
  12. Aug 10, 20268-K EDGAR
  13. Jul 16, 20268-K/A EDGAR
  14. Jul 8, 2026SCHEDULE 13D/A EDGAR
  15. Jul 7, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jun 23, 20268-K EDGAR
  17. Jun 16, 20268-K EDGAR
  18. Jun 11, 20268-K EDGAR
  19. May 27, 2026EFFECT EDGAR
  20. May 27, 2026424B5 EDGAR

The 208 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Craig Tooman$690.7K$2.2M53
2025Iain Ross72$17.0K$1.3M53
2025Rhonda Hellums54$490.0K$1.2M53
2025Steven RomanoM.D.66$490.0K$981.9K53
2024Former ChiefExecutive Officer$618.8K$3.7M53
2024Executive Vice PresidentChief Financial Officer$466.0K$1.7M53

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 72. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Siren, L.L.C.3,311,438$36.4M0.7%+400,000
TCG Crossover Management, LLC3,033,560$33.3M0.8%No change
Nantahala Capital Management, LLC2,693,462$29.6M0.9%+546,731
Redmile Group, LLC2,164,777$23.8M1.6%No change
Citadel Advisors LLC1,329,625$14.6M0.0%+94,818
Nextech Invest Ltd.952,400$10.5M0.5%No change
Millennium Management LLC909,279$10.0M0.0%−164,912
Tetragon Partners GP Ltd764,256$8.4M1.4%+134,095
Soleus Capital Management, L.P.630,000$6.9M0.2%New
Balyasny Asset Management L.P.610,980$6.7M0.0%New
5AM Venture Management, LLC476,200$5.2M1.8%No change
Great Point Partners LLC450,000$4.9M1.2%−570,489
Morgan Stanley403,172$4.4M0.0%+337,686
Ameriprise Financial Inc370,052$4.1M0.0%New
Jane Street Group, LLC369,151$4.1M0.0%+268,224
ADAR1 Capital Management, LLC338,373$3.7M0.2%+166,216
SummitTX Capital, L.P.326,648$3.6M0.1%New
Schonfeld Strategic Advisors LLC269,348$3.0M0.0%New
UBS Group AG243,152$2.7M0.0%−3,785
Ishara Investments LP55,350$2.4M1.8%−85,150
BlackRock, Inc.219,917$2.4M0.0%+15,140
Bank Of Montreal /can/201,734$2.2M0.0%−1,167
Boothbay Fund Management, LLC198,347$2.2M0.0%−10,741
Propel Bio Management, LLC191,733$2.1M1.1%New
Susquehanna International Group, Llp184,519$2.0M0.0%+69,238

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Silence Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSilence Therapeutics plc2
  • CIK0001479615
  • Employer ID (EIN)00-000000013
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company13
  • Incorporated inEngland and Wales13
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address12 Hammersmith Grove, Office 205, London, W6 7AP, United Kingdom2
  • Phone44-0-20-3457 69002
  • Shares outstanding141,740,037 as of Jul 31, 202612
  • Public float$206.2M as of Jun 30, 202513
  • AuditorPricewaterhouseCoopers LLP, Reading, United Kingdom PCAOB ID 876; no auditor attestation of internal control over financial reporting13
  • On EDGAR sinceJan 5, 20102
  • Filings271 in all: 6-K (67), 4 (42), 8-K (20), SC 13G/A (12), SC 13G (11), 3 (10), EFFECT (10), UPLOAD (8)2
    All 44 form types

    CORRESP (7), SCHEDULE 13D/A (7), 10-Q (5), 424B5 (5), POS AM (5), SC 13D/A (5), SCHEDULE 13G/A (5), 20-F (4), D (4), S-8 (4), 424B4 (3), SC 13D (3), 10-K (2), 6-K/A (2), 8-K/A (2), ARS (2), DEF 14A (2), F-1 (2), F-1/A (2), F-3 (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 10-K/A (1), 20-F/A (1), 424B3 (1), 424B7 (1), 8-A12B (1), CERT (1), DEL AM (1), DRS (1), DRS/A (1), DRSLTR (1), F-3ASR (1), PRE 14A (1), S-3 (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 5, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Aug 12, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing three ordinary shares, nominal value £0.05 per shareSLNThe Nasdaq Stock Market LLC
Ordinary share, nominal value £0.05 per shareThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 5, 2026 (Section 12(b) of the Exchange Act).13

Risk factors and legal proceedings

The risks Silence Therapeutics names in Item 1A of its 10-K filed Mar 5, 2026: 63 risks under these headings, as written.13

  • Risks Related to Our Financial Condition and Need for Additional Capital
  • We have a history of net losses, and we anticipate that we will continue to incur significant losses for the foreseeable future.
  • We have never generated any revenue from product sales and may never be profitable.
  • We will require additional financial resources to continue the ongoing development of our product candidates and pursue our business objectives. If we are unable to obtain these additional resources when needed or on acceptable terms, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates.
  • Raising additional capital may cause dilution to our holders, including holders of our ADSs, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Risks Related to the Discovery, Development, Regulatory Approval and Potential Commercialization of Our Product Candidates
  • The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.
  • We may not be successful in our efforts to identify or discover potential product candidates.
  • We may not be successful in our efforts to increase our pipeline, including by pursuing additional indications for our current product candidates, identifying additional indications for our proprietary platform technology or in-licensing or acquiring additional product candidates for other indications.
  • Preclinical studies and clinical trials of our product candidates may not be successful. If we are unable to generate successful results from these studies and trials, or experience significant delays in doing so, our business may be materially harmed.
  • If clinical trials of our product candidates fail to commence or, once commenced fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • Conducting successful clinical trials requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.
The other 52 risks
  • If we are unable to maintain any of our existing collaborations, or if these arrangements are not successful, or we are unable to enter into future licenses, our business could be adversely affected.
  • We rely on third parties to conduct some aspects of our manufacturing, research and development activities, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of research or clinical testing, or may terminate our agreements.
  • We rely on third-party manufacturers to produce our preclinical, clinical product candidates and certain starting material components, and we intend to rely on third parties to produce future clinical supplies of product candidates that we advance into clinical trials and commercial supplies of any approved product candidates.
  • Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.
  • Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements, and our products may face future development and regulatory difficulties.
  • We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
  • We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
  • Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third party payers and others in the medical community necessary for commercial success.
  • Risks Related to Our Business Operations and Compliance with Government Regulations
  • We face competition from other companies that are working to develop novel drugs and technology platforms using technologies similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.
  • If we fail to introduce new products or keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.
  • We face potential product liability and other claims, and, if successful claims are brought against us, we may incur substantial liability and costs.
  • Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and related tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.
  • We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign data privacy and security laws, regulations contractual obligations, industry standards, policies, and other obligations, and our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class actions); fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
  • Our employees, consultants and contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.
  • Our relationships with U.S. healthcare providers, including physicians, and third-party payers will be subject to applicable U.S. anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
  • Healthcare legislative and other regulatory reform measures may have a negative impact on our business and results of operations.
  • We may face uncertainty related to pricing, coverage and reimbursement for our product candidates.
  • Exchange rate fluctuations may adversely affect our results of operations and cash flows.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Inflation may adversely affect our operations, including increases in the prices of goods and services required for our operations.
  • Risks Related to our Intellectual Property
  • If we are unable to obtain or protect intellectual property rights related to our current or future products and product candidates, we may not be able to compete effectively in our markets.
  • Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • Risks Related to Our ADSs
  • We are a “smaller reporting company” and, as a result of the reduced disclosure requirements applicable to smaller reporting companies, our ADSs may be less attractive to investors.
  • We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.
  • The trading price of our ADSs may be volatile, and you could lose all or part of your investment.
  • Future sales, or the possibility of future sales, of a substantial number of our ADSs could adversely affect the price of such securities.
  • If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, the price and trading volume of our ADSs could decline.
  • Concentration of ownership of our ordinary shares (including ordinary shares represented by ADSs) among our existing senior management, directors and principal shareholders may prevent new investors from influencing significant corporate decisions and matters submitted to shareholders for approval.
  • Because we do not anticipate paying any cash dividends on our ordinary shares (including ordinary shares represented by ADSs) in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.
  • We may identify material weaknesses in our internal control over financial reporting in the future. If we experience material weaknesses or significant deficiencies in the future or otherwise fail to maintain an effective
  • system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.
  • If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.
  • Holders of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.
  • You may be subject to limitations on transfers of your ADSs.
  • The depositary for our ADSs is entitled to charge holders fees for various services, including annual service fees.
  • You may not receive distributions on our ordinary shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs.
  • Your right to participate in any future rights offerings may be limited, which may cause dilution of your holdings.
  • If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. Holders.
  • We may be unable to use U.K. carryforward tax losses to reduce future tax payments or benefit from favorable U.K. tax legislation.
  • Changes and uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.
  • Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.
  • Protections found in provisions under the U.K. City Code on Takeovers and Mergers, or the Takeover Code, will not apply if our place of management and control remains outside the United Kingdom.
  • The rights of our shareholders may differ from the rights typically offered to stockholders of a U.S. corporation.
  • As an English company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.
  • Claims of U.S. civil liabilities may not be enforceable against us.
  • Our articles of association provide that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.
  • ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable results for the plaintiff(s) in any such action.

Legal proceedings

From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. We do not currently have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results of operations, financial condition or cash flows. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.13

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53